Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. The company's clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy.

Axogen provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include: Avance Nerve Graft, which is an off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector, which is a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector, which is a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Entercom Communications is a holding company. Through its subsidiaries, Co, is a media and entertainment company primarily engaged in the sale of advertising time to local, regional and national advertisers and national network advertisers who purchase commercials in varying lengths. The company focuses on station-related digital product suites, which allow for audience interaction and participation, and integrated digital advertising solutions. The company's stations are classified by their format, such as news, sports, talk, classic rock, urban, adult contemporary, alternative and country, among others.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

Legacy Reserves is engaged in the acquisition and development of oil and natural gas properties. The company owns and operates oil and natural gas producing properties located primarily in East Texas, the Permian Basin (West Texas and Southeast New Mexico), Rocky Mountain and Mid-Continent regions of the United States. The company is focused on two activities: the acquisition of producing oil and natural gas properties and the development of properties in established producing trends. As of Dec 31 2016, the company had proved reserves of 144.8 million barrels of oil equivalent, consisting of 32.5 million barrels of oil, 7.8 million barrels of natural gas liquids, and 627 billion cubic feet of natural gas.

Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. In patients with metastatic breast cancer, tesetaxel was shown to have single-agent antitumor activity in two multicenter, Phase 2 studies. The company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Plumas Bancorp is a bank holding company. Through its subsidiary, Plumas Bank, the company serves the financial needs of individuals and businesses. The company's retail lending services include consumer, automobile and home equity loans. The company's commercial lending services include term real estate, commercial and industrial term loans. The company also provides government- guaranteed and agricultural loans as well as credit lines. The company's deposit products for the retail and commercial banking markets including checking, interest-bearing and premium interest-bearing checking, business sweep, public funds sweep, savings, time deposit and retirement accounts, as well as remote deposit, telephone and mobile banking.

RiceBran Technologies is an ingredient company serving food, animal nutrition and specialty markets focused on processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran, an underutilized by-product of the rice milling industry. The company converts raw rice bran into various products including: stabilized rice bran (SRB); RiBalance, a rice bran nutritional package derived from further processing of SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a protein and fiber rich insoluble derivative of RiBalance; and its family of ProRyza products, which includes derivatives composed of protein and protein/fiber blends.

Schlumberger provides technology for reservoir characterization, drilling, production and processing to the oil and gas industry. The company has four segments: Reservoir Characterization, which consists of the principal technologies involved in finding and defining hydrocarbon resources; Drilling, which consists of the principal technologies involved in the drilling and positioning of oil and gas wells; Production, which consists of the principal technologies involved in the lifetime production of oil and gas reservoirs; and Cameron, which consists of the principal technologies involved in pressure and flow control for drilling and intervention rigs, oil and gas wells and production facilities.

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing ribonucleic acid-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides (ERSG)) that are formulated to treat rare and ultra-rare premature stop codon diseases. ELX-02, the company's primary investigational drug product candidate, is a small molecule designed to restore production of functional proteins. ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. The company's preclinical candidate pool consists of a library of 170 ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.